Actuate Therapeutics, Inc. Common stock

8-K Delisting notice or listing-rule failure Jul 17, 2026 8-K Shareholder vote results May 22, 2026 10-Q Quarter ended 2026-03-31 May 14, 2026 8-K Regulation FD disclosure May 11, 2026 8-K Director or officer change; Other events May 6, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Regulation FD disclosure Jan 12, 2026 8-K Entered a material agreement Nov 28, 2025 8-K Other events Nov 21, 2025 10-Q Quarter ended 2025-09-30 Nov 13, 2025 8-K Entered a material agreement; Other events Sep 10, 2025 10-Q Quarter ended 2025-06-30 Aug 14, 2025 8-K Entered a material agreement; Unregistered sale of equity Jun 26, 2025 8-K Regulation FD disclosure Jun 5, 2025 8-K Regulation FD disclosure; Other events Jun 2, 2025 8-K Shareholder vote results May 23, 2025 10-Q Quarter ended 2025-03-31 May 15, 2025 8-K Other events May 6, 2025 8-K Entered a material agreement; Unregistered sale of equity Mar 28, 2025 10-K Fiscal year ended 2024-12-31 Mar 13, 2025 8-K Other events Feb 7, 2025 8-K Regulation FD disclosure Dec 17, 2024 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Regulation FD disclosure Nov 12, 2024 10-Q Quarter ended 2024-06-30 Sep 24, 2024 8-K Changed accountants Aug 19, 2024 8-K Director or officer change; Amended charter or bylaws; Other events Aug 14, 2024 4 May 22, 2026 4 May 22, 2026 4 May 22, 2026 4 May 22, 2026 4 May 22, 2026 4 May 22, 2026 4 May 22, 2026 S-8 INITIAL REGISTRATION STATEMENT May 14, 2026 3 May 6, 2026 DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS May 6, 2026 SCHEDULE 13G/A Apr 22, 2026 ARS 2025 ANNUAL REPORT Apr 9, 2026 DEFA14A Apr 6, 2026